Thank You for reading

RNA editing therapies on the horizon!

• Decoding Guide RNA Rules for Cas13. Research from Neville Sanjana's lab at the New York Genome Center opens the door to RNA editing therapies that can influence gene expression without making permanent genetic changes. The group recently cracked the code on guide RNA design rules for the RNA-targeting endonuclease Cas13. This means that researchers can now, for the first time, knock down any RNA in the human genome!

• Read more about Cas13 in our overview of CRISPR Cas endonucleases currently in focus for therapeutic applications.

Did you miss last weeks big news story?

• The COVID19 diagnostic kit made history as the first FDA-approved CRISPR application.CEO Rahul Dhanda told us the inside story of how Sherlock Biosciences developed the kit.

More good reads

• What diseases are likely to be cured by CRISPR? Check out this CRISPR infographic summarising CRISPR-related patent filings, clinical trials and top CRISPR industry players worldwide.
• Researchers in Germany develop a simple method to detect unintended on-target events and show in Cell Reports that they happen quite often in stem cells.
• Intellia Therapeutics prepares to seek regulatory green light to progress gene-editing candidate NTLA-2002 for the treatment of hereditary angioedema (HAE) into clinical studies by next year.
• CRISPR-Cas9 mutations help to reveal early-stage development path for ovarian cancer in fallopian tube organoids. On that note, some of the same researchers previously used CRISPR to cure cystic fibrosis in patient-derived organoids.

Thank You for now - more great reads are on the way.

And if you have questions or suggestions, you can directly reach us at editor@crisprmedicinenews.com. We love hearing from readers!

(c; Rasmus

You can follow the blog on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up yourself here.